FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

 OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * Jordan Julie 2. Date of Event Requiring Statement (MM/DD/YYYY)
3/7/2023 

 3. Issuer Name and Ticker or Trading Symbol Homology Medicines, Inc. [FIXX]
(Last)        (First)        (Middle)
C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Medical Officer /
(Street)
BEDFORD, MA 01730      
(City)              (State)              (Zip)
 5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock  2519  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy)   (1) 6/2/2031  Common Stock  65000  $6.53  D   
Employee Stock Option (Right to Buy)   (2) 2/24/2032  Common Stock  56000  $2.71  D   
Employee Stock Option (Right to Buy)   (3) 3/2/2032  Common Stock  9000  $3.59  D   
Employee Stock Option (Right to Buy)   (4) 2/23/2033  Common Stock  143000  $1.60  D   
Restricted Stock Units   (5)  (6) Common Stock  350   (6) D   
Restricted Stock Units   (7)  (6) Common Stock  5360   (6) D   
Restricted Stock Units   (8)  (6) Common Stock  1340   (6) D   
Restricted Stock Units   (9)  (6) Common Stock  24000   (6) D   

Explanation of Responses:
(1)  The option vests or has vested as to 25% of the underlying shares on May 3, 2022 and in 36 substantially equal monthly installments upon the Reporting Person's completion of each full month of service thereafter so that such option will become fully vested on May 3, 2025.
(2)  The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2022 so that such option will become fully vested on January 1, 2026.
(3)  The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2022 so that such option will become fully vested on January 1, 2026.
(4)  The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2023 so that such option will become fully vested on January 1, 2027.
(5)  The restricted stock units will vest and settle in full on August 2, 2023.
(6)  Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date.
(7)  The restricted stock units will vest and settle as to one half of the restricted stock units on each of January 1, 2024 and January 1, 2025.
(8)  The restricted stock units will vest and settle as to one half of the restricted stock units on each of January 1, 2024 and January 1, 2025.
(9)  The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2023 so that such RSUs will become fully vested on January 1, 2026.

Remarks:
Exhibit 24 - Power of Attorney.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Jordan Julie
C/O HOMOLOGY MEDICINES, INC.
ONE PATRIOTS PARK
BEDFORD, MA 01730

Chief Medical Officer

Signatures
/s/ Paul Alloway, Attorney-in-Fact for Julie Jordan 3/16/2023
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Aug 2023 to Sep 2023 Click Here for more Homology Medicines Charts.
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Sep 2022 to Sep 2023 Click Here for more Homology Medicines Charts.